255 completed, 26 unknown, 16 terminated, 6 withdrawn. 76 Phase 3, 65 Phase 1, 64 Phase 4, 63 Phase 2, 43 Not applicable.
Follow this drug Literature Review of efavirenz trials Research Report on efavirenz
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants Clifutinib, Itraconazole, fluconazole - Healthy Adult Subject | Phase 1 | Not yet recruiting | Sunshine Lake Pharma Co., Ltd. | 80 | 2026-12-31 | 2026-04-27 |
| Drug-Drug Interactions of JMKX003142 in Healthy Participants JMKX003142 tablets, Fluconazole Capsules, Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets) - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 1 | Not yet recruiting | Jemincare | 112 | 2026-05-11 | 2026-05-04 |
| Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants Suzetrigine, Efavirenz - Pain | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 18 | 2026-05-07 | 2026-08-18 |
| Efavirenz for the Treatment of Creutzfeldt-Jakob Disease Efavirenz, Placebo - Creutzfeldt-Jakob Disease | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | 246 | 2026-04-14 | 2026-09-03 |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Drug-Drug Interaction Potential of Mavorixafor Mavorixafor, Carbamazepine, Efavirenz - Healthy Participants | Phase 1 | Completed | X4 Pharmaceuticals | 38 | 2025-02-18 | 2025-07-01 |
| A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) MK-7602, Efavirenz - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 34 | 2025-02-10 | 2025-08-22 |
| The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY Efavirenz 600mg - Hiv | Not applicable | Recruiting | University of Toronto | 26 | 2025-01-14 | 2026-03-17 |
| Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Methadone and Tizanidine, Efavirenz, Methadone and Tizanidine - Drug-Drug Interaction | Early Phase 1 | Recruiting | Indiana University | 60 | 2023-10-06 | 2026-08-20 |
| A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults TAK-279, Erythromycin, Phenytoin - Healthy Volunteers | Phase 1 | Completed | Takeda | 172 | 2023-08-11 | 2024-02-06 |
| A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) Nemtabrutinib, Efavirenz - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2023-07-25 | 2024-11-20 |
| An Open-label DDI Study of Omaveloxolone in Healthy Subjects Omaveloxolone, Efavirenz - Healthy Adult Subjects | Phase 1 | Completed | Biogen | 20 | 2023-07-05 | 2025-05-30 |
| Efavirenz (EFV) Intensification Efavirenz 600mg - HIV | Phase 4 | Completed | Washington University School of Medicine | 9 | 2023-02-09 | 2026-07-17 |
| A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects SHR1459 tablet, Efavirenz tablet - B-cell Tumors | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2022-11-04 | 2023-02-02 |
| Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers Arm 1: Radix Puerariae lobatae (Gegen), Arm 1: Six-probe drug cocktail, Arm 2: Radix Puerariae lobatae (Gegen) - Herb-drug Interactions | Phase 1 | Completed | Chinese University of Hong Kong | 56 | 2022-08-08 | 2026-10-05 |
| Reverse Triple Negative Immune Resistant Breast Cancer Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate - Triple-negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 80 | 2022-06-30 | 2025-12-03 |
| Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz Ganaplacide, Lumefantrine, Efavirenz - Malaria | Phase 1 | Completed | Novartis Pharmaceuticals | 14 | 2022-04-28 | 2023-01-12 |
| A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants Abrocitinib, Omeprazole, Caffeine - Healthy Participants | Phase 1 | Completed | Pfizer | 26 | 2021-10-21 | 2024-05-31 |
| Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection B/F/TAF, TDF/3TC/EFV - HIV-1-infection | Phase 4 | Completed | Peking Union Medical College Hospital | 202 | 2021-07-14 | 2026-06-05 |
| Flucloxacillin as an Inducer of CYP-enzymes Flucloxacillin - Healthy Volunteers, Drug Drug Interaction | Phase 1 | Completed | University of Southern Denmark | 14 | 2021-03-25 | 2022-01-11 |
Showing 20 of 314. Sign in to see all of them.
HIV Infections (192) · Acquired Immunodeficiency Syndrome (50) · Tuberculosis (21) · Hepatitis C (8) · Infections (7) · Lipodystrophy (6) · Malaria (6) · Hepatitis B (4) · Coinfection (3) · HIV Seropositivity (3) · Anxiety Disorders (2) · Breast Feeding (2) · Cardiovascular Diseases (2) · Depression (2) · Immunologic Deficiency Syndromes (2)
National Institute of Allergy and Infectious Diseases (NIAID) (45) · Bristol-Myers Squibb (17) · French National Agency for Research on AIDS and Viral Hepatitis (9) · Gilead Sciences (8) · St Stephens Aids Trust (8) · ANRS, Emerging Infectious Diseases (7) · Kirby Institute (7) · Merck Sharp & Dohme LLC (7) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (6) · University of California, San Francisco (6) · ViiV Healthcare (6) · Glaxo Wellcome (5) · Indiana University (5) · Tibotec Pharmaceuticals, Ireland (5) · Abbott (4)
United States (145) · Puerto Rico (37) · South Africa (33) · Thailand (29) · France (25) · Spain (24) · Brazil (23) · United Kingdom (22) · Canada (19) · Uganda (19) · China (16) · Argentina (15) · Germany (15) · Mexico (14) · Australia (11)
Scott Hammer (4) · Bonaventura Clotet, MD, PhD (3) · Diane Havlir, MD (3) · Zeruesenay Desta, PhD (3) · Ann Collier (2) · Bernard BH Hirschel, Professor (2) · David Wohl (2) · Diane Havlir (2) · Genevieve Chene, MD, PhD (2) · Grant Dorsey, MD, PhD (2)
PMID 24979445, PMID 33901188, PMID 24326304, PMID 32829410, PMID 38160309, PMID 20133267, PMID 21436711, PMID 22532465, PMID 23714781, PMID 10601506, PMID 11069252, PMID 11306155, PMID 11399973, PMID 11964551, PMID 12934177, PMID 14668455, PMID 14668456, PMID 14669723, PMID 14982784, PMID 15090769, PMID 15097312, PMID 15115831, PMID 15187476, PMID 15316349, PMID 15356820, PMID 15717256, PMID 15750390, PMID 16048950, PMID 16048984, PMID 16091248, PMID 16103764, PMID 16267764, PMID 16287792, PMID 16421366, PMID 16470119, PMID 16514303, PMID 16782488, PMID 16810109, PMID 16816555, PMID 16886163, PMID 16905783, PMID 16988514, PMID 17109339, PMID 17174704, PMID 17310819, PMID 17357053, PMID 17527093, PMID 17591032, PMID 17662759, PMID 17726714
U01AI068636 (5), 2005 (3), 2009 (3), K24AI051966 (3), 2004 (2), 2014 (2), R01GM078501 (2), U19AI053217 (2), 2008 (1), K23AI070078 (1), K23AI077355 (1), P01HD059454 (1), R01AI062512 (1), R01AI065256 (1), R01AI083036 (1)